Aquestive TherapeuticsAQST
About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Employees: 135
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
188% more call options, than puts
Call options by funds: $1.9M | Put options by funds: $661K
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
0.44% more ownership
Funds ownership: 46.22% [Q1] → 46.66% (+0.44%) [Q2]
3% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 31
1% less funds holding
Funds holding: 97 [Q1] → 96 (-1) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
38% less capital invested
Capital invested by funds: $177M [Q1] → $110M (-$66.7M) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
JMP Securities Jason Butler 60% 1-year accuracy 18 / 30 met price target | 83%upside $9 | Market Outperform Reiterated | 8 Oct 2024 |
JMP Securities Jason Butler 60% 1-year accuracy 18 / 30 met price target | 83%upside $9 | Market Outperform Reiterated | 30 Sept 2024 |
Leerink Partners Roanna Ruiz 100% 1-year accuracy 5 / 5 met price target | 144%upside $12 | Outperform Reiterated | 30 Sept 2024 |
HC Wainwright & Co. Raghuram Selvaraju 56% 1-year accuracy 133 / 239 met price target | 103%upside $10 | Buy Maintained | 30 Sept 2024 |
HC Wainwright & Co. Raghuram Selvaraju 56% 1-year accuracy 133 / 239 met price target | 83%upside $9 | Buy Reiterated | 14 Aug 2024 |